Table 1 Modulation of gut microbiota in brain cancer patients based on findings from randomised studies
From: Gut microbiota and their influence in brain cancer milieu
Cancer subtype/Number of patients | Microorganism/metabolites | Effect on glioblastoma | Reference |
|---|---|---|---|
Glioblastoma patients (n = 91), Control subjects (n = 218,701) | family Ruminococcaceae, genus Anaerostipes, genus Faecalibacterium, genus LachnospiraceaeUCG004, genus Phascolarctobacterium, genus Prevotella7, genus Streptococcus | ↓Risk | [171] |
family Peptostreptococcaceae, genus Eubacteriumbrachy group | ↑Risk | [171] | |
Glioblastoma patients (n = 91), Control subjects (n = 218,701) | family Peptostreptococcaceae, family Ruminococcaceae, family Victivallaceae, genus Eubacteriumbrachygroup, genus Eubacteriumruminatiumgroup, genus Anaerostipes, genus Faecalibacterium, genus LachnospiraceaeUCG004, genus Prevotella7, genus RikenellaceaeRC9gutgroup, genus Senegalimassilia | Causal association | [172] |
Glioblastoma patients (n = 162), Control subjects (n = 256,583) | family Ruminococcaceae | ↓Risk | [173] |
family Bacteroidaceae, family Peptococcaceae, genus Eubacterium (brachy group), genus Actinomyces, genus Bacteroides, genus Ruminiclostridium6 | ↑Risk | [173] | |
Glioblastoma patients (n = 91) Control subjects (n = 174,006) | phylum Cyanobacteria, family Erysipelotrichaceae, family Prevotellaceae, genus Eubacterium nodatum group, genus Lachnoclostridium | Protective factors | [174] |
family Rikenellaceae, family Victivallaceae, family Ruminococcus gnavus group, family Lactococcus, family Ruminococcaceae UCG002, family Sellimonas, order Desulfovibrionales | ↑Risk | [174] | |
Imidazole lactate, N4-acetylcytidine, 1-ribosyl-imidazoleacetate, 1-stearoyl-2-oleoyl-GPE (18:0/18:1), 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2), Androstenediol (3beta,17beta) monosulfate (2), 1-stearoyl-2-linoleoyl-GPE (18:0/18:2), 1-stearoyl-2-arachidonoyl-GPE (18:0/20:4), 1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4), 1-oleoyl-2-arachidonoyl-GPE (18:1/20:4), 1-oleoyl-2-linoleoyl-GPE (18:1/18:2), Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC), Dihomo-linoleoylcarnitine (C20:2), 1-palmitoyl-2-oleoyl-GPE (16:0/18:1), X-15523 | ↑Risk | [174] | |
Beta-hydroxyisovalerate, 1-palmitoyl-2-oleoyl-GPE (16:0/18:1), X-21607, Decadienedioic acid (C10:2-DC), Retinol (Vitamin A) to oleoyl-linoleoyl-glycerol (18:1–18:2) | ↓Risk | [174] | |
GBM patients (n = 243), Control subjects (n = 287,137) | family Victivallaceae, genus Lactococcus | ↑Risk | [314] |
phylum Cyanobacteria | Protective factor | [314] | |
Glioma patients (n = 3,301) | family Peptostreptococcaceae, genus Coprobacter, genus Olsenella | Protective factor | [315] |
family Verrucomicrobia, family Prevotella7, family Euryarchaeota, genus Adlercreutzia, genus Catenibacterium | ↑Risk | [315] |